PROGRAM
MONDAY, 20 JUNE, 2016

WELCOME
8:45am - 9:10am
Hall A

KEYNOTE 1 - MARTIN EILERS
9:10am - 9:55am
Chair: Garrett Brodeur

9:10am  Martin Eilers
Complexes of N-MYC and MYC with Aurora-A: an inroad to targeting MYC function for neuroblastoma therapy  abs# 1

PLENARY SESSION 1
9:55am - 10:30am
Chairs: William Weiss & Barbara Hero

9:55am  Shoma Tsubota
The role of PRC2 in the early neuroblastoma tumorigenesis in MYCN-Tg mice  abs# 2
10:11am  Kevin Freeman
Transforming primary neural crest cells to model neuroblastoma reveals a lineage sensitivity to BET inhibitors  abs# 3

MORNING TEA
10:30am - 11:00am
Exhibition Area
PARALLEL 1 - ONCOGENESIS
11:00am - 12:30pm  Meeting room 1 & 2
Chairs: Akira Nakagawara & Belamy Cheung

11:00am  **Miller Huang**
Human pluripotent stem cell-based models of MYCN-amplified neuroblastoma  abs# 4

11:15am  **Bieke Decaestecker**
SOX11 acts as part of the MYCN regulatory protein complex implicated in neuroblastoma  abs# 5

11:30am  **Shizhen (Jane) Zhu**
Aberrant activation of SHP2 cooperates with MYCN in neuroblastoma pathogenesis  abs# 6

11:45am  **Annick Mühlethaler-Mottet**
The ALK-F1174L activating mutation mediates the upregulation of gene cluster located in the 15qD1 genomic region including the Myc locus in tumors derived from murine neural crest progenitor cells  abs# 7

12:00pm  **Isabelle Janoueix-Lerosey**
Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis  abs# 8

12:15pm  **Carol Thiele**
Reactivation of cAMP /PKA pathway is an early event that relieves EZH2-mediated epigenetic suppression in High-Risk Neuroblastoma(HR-NB)  abs# 9

PARALLEL 2 - LIQUID BIOPSIES, CIRCULATING TUMOUR CELLS AND METASTASIS
11:00am - 12:30pm  Hall A
Chairs: Frank Berthold & Klaus Beiske

11:00am  **Mathieu Chicard**
Whole exome sequencing of circulating free tumour DNA for study of spatial and temporal tumor heterogeneity: accumulation of new mutations at tumor progression of neuroblastoma  abs# 10

11:15am  **Martina Morini**
Liquid biopsies reveal exosomal miRNA modulation in high-risk neuroblastoma patients after the induction therapy  abs# 11

11:30am  **Katleen De Preter**
Detection of copy number aberrations in cell free DNA from plasma of neuroblastoma patients using shallow massive parallel sequencing  abs# 12

11:45am  **Fikret Rifatbegovic**
The transcriptomic landscape of bone marrow-derived disseminated tumor cells of high-risk neuroblastoma patients  abs# 13

12:00pm  **Alex BK Seong**
A novel neuroblastoma metastatic mouse model identifies genes, pathways and drugs regulating metastasis  abs# 14

12:15pm  **Giuseppe Barone**
A native and immunocompetent in vivo model of chemorefractory, bone-marrow metastatic, “ultra-high risk” neuroblastoma.  abs# 15

LUNCH
12:30pm - 1:30pm  Exhibition Area
NEUROBLASTOMA CONSORTIUM MEETING
12:30pm - 1:30pm
Conference Room 5

INDUSTRY SPONSORED WORKSHOP: APEIRON
12:45pm - 1:25pm
Meeting room 1 & 2

R2 PLATFORM WORKSHOP: ONLINE PUBLIC RESOURCE FOR NEUROBLASTOMA OMICS DATA
12:50pm - 1:20pm
Hall A

PARALLEL 3 - TERT AND OTHER NOVEL TARGETS
1:30pm - 3:00pm
Hall A
Chairs: Jo Vandesompele & Arata Tomiyama

1:30pm  Andrea Kraemer
The prognostic and therapeutic relevance of TERT activation in neuroblastoma
abs# 16

1:45pm  Eiso Hiyama
Telomere biology in neuroblastoma: focusing on alteration of TERT promoter lesion
abs# 17

2:00pm  Balakrishna Koneru
Constitutive activation of ATM kinase in neuroblastoma cell lines with the alternative lengthening of telomeres (ALT) phenotype induces resistance to DNA damaging agents
abs# 18

2:15pm  Rebecca Dagg
A unique mechanism for the continual proliferation of high-risk neuroblastoma cells
abs# 19

2:30pm  Jessica Koach
Targeting a novel MYCN onco-factor, PA2G4, for the treatment of neuroblastoma
abs# 20

2:45pm  Per Kogner
Targeting tumor-promoting neuroblastoma microenvironment; Inhibition of tumor development and progression by therapy targeting mPGES-1 and prostaglandin E₂ expression in cancer associated fibroblasts
abs# 21
PARALLEL 4 - NOVEL THERAPIES AND IMMUNOTHERAPY
1:30pm - 3:00pm
Meeting room 1 & 2
Chairs: Alex Swarbrick & Ro Bagatell

1:30pm  Alessandro Quattrone
Targeting the LIN28B/let-7 axis by small molecules in neuroblastoma

1:45pm  Meredith Irwin
A small molecule kinome inhibitor screen identifies the TGF-beta-activated kinase 1 (TAK1) as a target for combination therapy in MYC-driven neuroblastoma

2:00pm  Vandana Batra
Preclinical characterization of meta-[^{211}At]astatobenzylguanidine ([^{211}At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma

2:15pm  Robyn T Sussman
A CD56 (NCAM1) targeting antibody-drug conjugate is potently effective in preclinical models of high-risk neuroblastoma

2:30pm  Kristopher R Bosse
GPC2 is a putative oncogene and candidate immunotherapeutic target in high-risk neuroblastoma

2:45pm  Shakeel Modak
Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus GM-CSF: High dosing and major responses in patients with resistant high-risk neuroblastoma (HR-NB)

AFTERNOON TEA
3:00pm - 3:30pm
Exhibition Area
WORKSHOP 1 - EPIGENETIC REGULATION AND GENOME EDITING IN CANCER

3:30pm - 5:00pm

Hall A

Moderator: Frank Speleman

The study of epigenetic deregulation of cancer cells has moved to the forefront of cancer research as a result of the recent discovery that across all tumor entities roughly 20% of all mutations affect genes implicated in processes controlling methylation and chromatin modification. At the same time, an increasing number of novel epigenetic drugs are emerging and going through in vitro, pre-clinical and clinical testing. CRISPR/Cas technology has revolutionized controlled genome editing offering new exciting possibilities to investigate the complex epigenetic control of gene expression in cancer cells even down to the single cell level. In this workshop we bring together experts in this field explaining how new insights into the highly complex epigenetic regulatory processes can provide deeper understanding of tumor initiation, progression and therapy resistance and how genome editing can aid to further fuel this discovery process, ultimately providing us the tools and data to identify novel drug targets and therapeutic strategies to combat neuroblastoma.

3:30pm  Stanley Qi  
CRISPR/Cas9 based genome editing

4:00pm  Tim Mercer
Putting genes under the microscope: an exploration of the human transcriptome

4:20pm  Kevin Freeman
Exploring the role of chromatin remodeling factors in neuroblastoma oncogenesis using genome-editing of mice neural crest progenitors

4:32pm  Jason Shohet
Defining epigenetic drug targets in neuroblastoma; structure is function

4:44pm  Round Table Discussion
WORKSHOP 2 - NOVEL CLINICAL TRIAL DESIGN FOR ADVANCED NEUROBLASTOMA: A DEBATE

3:30pm - 5:00pm

Moderator: Glenn Marshall

Meeting room 1 & 2

Much of the pre-clinical and clinical research on neuroblastoma is aimed at discovering more effective therapy for the majority of children who present with clinically advanced disease. Even successful current therapy for advanced neuroblastoma can lead to severe short and longterm side-effects, indicating the need for improved treatment strategies. Recent advances in organic chemistry and structure-aided design have seen a marked increase in the number of available targeted anticancer drugs, but the relative rarity of neuroblastoma may mean that novel trial designs are required to more rapidly incorporate pre-clinical advances into frontline protocols. This significant shift, coupled with more sophisticated methods of minimal residual disease monitoring, techniques for detailed analysis of tumor heterogeneity and 'window therapy' trial designs used to assess treatment efficacy in real-time, suggest that traditional single comparison phase 3 trial designs may no longer be suited to the problem of incorporating promising single agent or combination therapies into the treatment of newly diagnosed patients. The advent of precision or personalised oncologic medicine, aimed at better matching the treatment to the target holds the promise of improved cure rates and lower side-effect profiles. However, the relatively low number of genomic targets in neuroblastoma and the poor availability of novel agents for paediatric patients, means the field faces significant clinical research challenges in the future. We have asked the leaders of frontline international Phase 3 clinical trials for advanced neuroblastoma and early phase trialists to debate the following hypothesis: “That a conventional single comparison, randomised, Phase 3 trial design is no longer appropriate for newly diagnosed advanced neuroblastoma patients”.

3:30pm  Introductory remarks
3:35pm  Pre-debate Voting
3:40pm  Ruth Ladenstein
        Chair, SIOPEN-HR1; St. Anna Kinderkrebsforschung e.V. & Children's Cancer Research Institute
        Vienna, Austria
3:55pm  Julie Park
        Chair, COG Neuroblastoma Steering Committee; Seattle Childrens Hospital & University of
        Washington, Seattle, USA
4:10pm  Angelika Eggert
        Chair, German Neuroblastoma Trial Group; Charité Universitätsmedizin Berlin, Germany
4:25pm  David Ziegler
        Co-Chair, NANT Phase I/II DFMO trial; Sydney Children's Hospital, Sydney Australia
4:40pm  Questions from the floor
4:55pm  Post-debate voting
RAPID FIRE POSTER PRESENTATION 1
5:05pm - 5:25pm

Christine Gana
New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma

abs# 249

Hedi Deubzer
The MCM complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells

abs# 188

Lara Riehl
The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse

abs# 198

Sela T Po’uha
Stathmin expression regulates miR-382/PTPN14 expression in neuroblastoma cells

abs# 256

Giuseppe Giannini
The MRN complex controls replication stress and allows proliferation and survival in MYCN amplified neuroblastoma

abs# 250

Robyn T Sussman
CAMKV is a candidate immunotherapeutic target in MYCN-amplified neuroblastoma.

abs# 226

Amos HP Loh
Proteomic analysis of high-risk neuroblastoma identifies nuclear distribution protein C as a marker of differentiation and prognosis

abs# 177

Laurel T. Bate-Eya
EZH2 is highly expressed in neuroblastoma and plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

abs# 187

Godelieve Tytgat
Circulating tumor DNA for disease monitoring in neuroblastoma

abs# 171

W. Clay Gustafson
Aurora Kinase A inhibition sensitizes neuroblastoma to $^{131}$I-MIBG

abs# 173

Navin Pinto
Isolation of circulating tumour and associated cells by microfiltration in patients with neuroblastoma

abs# 169

Barbara Hero
Survival tree analysis of an independent cohort reveals risk factors as proposed in the INRG system

abs# 162

Claudia Pasqualini
Survival and prognostic factors for children 12 to 18 months of age with stage 4 non-MYCN amplified neuroblastoma treated in the SIOPEN high-risk trial

abs# 168

Shakeel Modak
Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma

abs# 221

Ulrike Pötschger
Impact of age and MNA amplification (MNA) on long-term survival rates: accurate estimation and refined modeling using innovative statistical approaches. A SIOPEN study from the high risk neuroblastoma trial HR-NBL1/SIOPEN.

abs# 170

Alvin Kamili
Ex vivo drug screening as a strategy for personalised therapy in high-risk neuroblastoma

abs# 174
POSTER SESSION 1 WITH WINE & CHEESE

5:25pm - 7:00pm  
Hall C + D

For those with specific interest in abstracts from the Basic, Clinical or Translational categories please use the lists located on page 129 as you walk amongst the posters to find them easily. Posters are arranged in the Exhibition Area in consecutive numerical order. Should you wish to view the entire list of poster abstracts in either Basic, Clinical or Translation divisions, please refer to the ‘app’ where you will find the posters sorted by category. Further information on the ‘app’ is available on page 22. Below is a complete listing of all posters in the Monday evening poster session.

Sponsored by

M. Reza Abbasi  
Impact of bone marrow-derived disseminated neuroblastoma cells on the identification of the relapse seeding clone  
abs# 151

Shifra Ash  
Analyzing risk factors for stem-cell collection failure in patients on the High-Risk Neuroblastoma 1 trial (HR-NBL1/SIOOPEN)  
abs# 152

Klaus Beiske  
Quantification of bone marrow disease in high risk neuroblastoma patients by anti-GD2 immunocytochemistry – impact on survival. A SIOOPEN High Risk Study  
abs# 153

Pablo Berlanga  
Central imaging review in the SIOOPEN high-risk neuroblastoma trial: preliminary data on central nervous system recurrences  
abs# 154

Frank Berthold  
Characteristics and risk factors of 517 patients with first recurrence from stage 4 neuroblastoma over 18 months  
abs# 155

Sue A Burchill  
Detection of PHOX2B and TH mRNA by RTqPCR in peripheral blood stem cell harvests may identify children with stage 4 neuroblastoma that have an increased risk of an event post reinfusion: a SIOOPEN study  
abs# 156

Louis Chesler  
Genome-wide analysis of liquid biopsies reveals a novel layer of tumor heterogeneity in neuroblastoma  
abs# 157

Valérie Combaret  
Detection of tumor ALK Status in neuroblastoma patients using peripheral blood  
abs# 158

Susanne Fransson  
Amplification of CDK4 and MDM2 is associated with atypical clinical features in high risk neuroblastoma patients  
abs# 159

Mark N Gaze  
A comparison of 123I-mIBG planar imaging and SPECT/CT with 68Ga-DOTATATE PET/CT for staging and response assessment of high-risk neuroblastoma  
abs# 160

Jo Lynne Harenza  
Development of a targeted sequencing panel for detection of subclonal mutations in neuroblastoma at diagnosis  
abs# 161

Barbara Hero  
Survival tree analysis of an independent cohort reveals risk factors as proposed in the INRG system  
abs# 162

MoonSun Jung  
An 18-gene Myc activity signature predicts poor clinical outcome in multiple Myc-associated cancer types  
abs# 163

Denis Kachanov  
Opsoclonus myoclonus syndrome in children with neuroblastoma  
abs# 164

Natalia M Khranovska  
Prognostic and predictive significance of p53, MDM2 and miRNAs gene expression in patients with neuroblastoma  
abs# 165

Teofila Książek  
Microarray CGH analysis of genomic imbalances in neuroblastoma FFPE specimens – pilot study  
abs# 166

Noritaka Miyazawa
Clinical characteristics and risk factor of transplantation-associated microangiopathy (TAM) in high-risk neuroblastoma undergoing autologous peripheral blood stem cell transplantation (auto-PBSCT)  
**Claudia Pasqualini**  
Survival and prognostic factors for children 12 to 18 months of age with stage 4 non-MYCN amplified neuroblastoma treated in the SIOPEN high-risk trial  
**Navin Pinto**  
Isolation of circulating tumor and associated cells by microfiltration in patients with neuroblastoma  
**Ulrike Pötschger**  
Impact of age and MNA amplification (MNA) on long-term survival rates: accurate estimation and refined modeling using innovative statistical approaches. A SIOPEN study from the high risk neuroblastoma trial HR-NBL1/SIOPEN.  
**Godelieve Tytgat**  
Circulating tumor DNA for disease monitoring in neuroblastoma  
**Jalenka van Wijk**  
A flow cytometry backbone panel as a first step in detection of circulating tumor cells in neuroblastoma  
**W. Clay Gustafson**  
Aurora Kinase A inhibition sensitizes neuroblastoma to $^{131}$I-MIBG  
**Alvin Kamili**  
*Ex vivo* drug screening as a strategy for personalised therapy in high-risk neuroblastoma  
**Daisuke Kaneda**  
A novel histone deacetylase inhibitor OBP-801 induces apoptosis in neuroblastoma tumor cells  
**Loretta MS Lau**  
Serum C-circles as biomarker of Alternative Lengthening of Telomeres (ALT) in neuroblastoma  
**Amos HP Loh**  
Proteomic analysis of high-risk neuroblastoma identifies nuclear distribution protein C as a marker of differentiation and prognosis  
**Ferro Nguyen**  
Targeted drug delivery using nanoparticles (NPs) in neuroblastoma (NB) xenografts  
**Maike Nortmeyer**  
Bromodomain-inhibition as therapeutic option for *MYCN*-amplified neuroblastoma  
**Jed G Nuchtern**  
The Connectivity Map bioinformatics platform identifies agents that reverse the chemotherapy resistance phenotype in neuroblastoma  
**Alessandro Quattrone**  
A screening for natural products identifies a flavonol as a synergistic compound with 13-cis retinoic acid in neuroblastoma  
**Nilay Shah**  
CYP26-mediated metabolism of retinoids is a putative mechanism of treatment resistance in neuroblastoma  
**Justine Stehn**  
Anti-tropomyosin agents enhance the antitumor effectiveness of microtubule inhibitors in preclinical models of neuroblastoma  
**Carol J Thiele**  
Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases tumor-initiating potential of neuroblastoma cells and increases their chemosensitivity  
**Hiroyuki Yoda**  
Targeting the *MYCN* oncogene in *MYCN*-amplified neuroblastoma with a novel PI polyamide DNA-alkylating drug conjugate  
**Libo Zhang**  
Combined antitumor therapy with metronomic administration of topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma preclinical models  
**Laurel T. Bate-Eya**  
EZH2 is highly expressed in neuroblastoma and plays an important role in
neuroblastoma cell survival independent of its histone methyltransferase activity
Hedi Deubzer
The MCM complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells
Moritz Gartlgruber
A genome-wide MYCN synthetic lethal screen identifies inhibition of PRC2 as drug target in MYCN-amplified neuroblastoma cells
Venkatadri Kolla
Epigenetic silencing of CHD5 expression by histone modification in human neuroblastoma
Jan Koster
R2: A public user-friendly website for integrated analysis of genomic data and associated clinical parameters in neuroblastoma
Tim Lammens
Non-random pattern of whole chromosome gains and losses in neuroblastoma with numerical chromosomal aberrations
Koumudi Naraparaju
Role of MiRNAs in the epigenetic silencing of CHD5, a tumor suppressor in neuroblastoma (NB)
Miki Ohira
Clinical relevance of genomic and epigenomic classification of MYCN-non-amplified neuroblastoma
Miki Ohira
Genomic characterization of high-risk neuroblastoma in Japan: A retrospective study of 537 cases by using updated follow-up data based on INRG variables [Japan Neuroblastoma Study Group (JNBSG)]
Chi Yan Ooi
MicroRNA-204 suppresses neuroblastoma tumour growth through down-regulation of MYCN oncogene
Alessandro Quattrone
Exploring m6A mRNA methylation for novel therapeutic chances in neuroblastoma
Lara Riehl
The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse
Ya-Hui Tsai
CPEB1 down-regulated the expression of MYCN via tumor-suppressor miRNA let-7 in human neuroblastoma cells
Kumiko Uryu
Genetic characteristics of 494 neuroblastomas using genome-wide analysis combined with immunohistochemistry
David Cantelmi
End of life care for children with neuroblastoma: a retrospective study from the Royal Children Hospital Brisbane
Angela Cha
Physeal arrest leading to angular deformity after therapy with isotretinoin for high risk neuroblastoma (HR-NBL)
Hsiu-Hao Chang
A multidisciplinary team care improved outcomes for children with high-risk neuroblastoma
Matthew D Aldridge
The requirement for accurate standardization and methodology of dosimetry in international trials incorporating molecular radiotherapy (MRT) in the treatment of high-risk neuroblastoma
Stephane Birkle
Antibodies specific for O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia
Tom Boterberg
Importance of quality assurance in radiotherapy for optimal local control. A report from the SIOPEN radiotherapy committee of the High Risk Neuroblastoma Trial (HR-NBL1/SIOPEN)

Bao C Bui
Stromal collagen type XI alpha 1 COL11A1 expression in neuroblastoma

Angela Cha
Dinutuximab combined with chemotherapy in patients with multiply relapsed/refractory high risk neuroblastoma (HR-NBL)

Godfrey CF Chan
Evaluation of genetic modified anaerobic Salmonella typhimurium as therapy for neuroblastoma: Comparison of response of orthotopic mouse models with different immunological backgrounds

Maria V Corrias
Preclinical studies of anti-PDL-1/PD-1-based combination immunotherapy for Neuroblastoma

Eoin Dodson
Which miRNAs should be developed into novel therapeutics for neuroblastoma?

Christin Eger
Generation and characterization of a new chimeric human/mouse anti-idiotypic antibody ganglidiximab for active immunotherapy against neuroblastoma

Barbara Hero
Role of Surgery in Patients older than 18 months with localized Neuroblastoma (Stage 1-3)

Meredith Irwin
More is less: radiation exposure to family caregivers and health care providers of paediatric neuroblastoma patients receiving $^{131}$I-MIBG therapy in Canada

Eugene S Kim
Anti-GD2 antibody combined with activated natural killer cells leads to improved survival and decreased metastasis in a minimal residual disease mouse model of neuroblastoma

Li-Ling Lin
TLR3-Mediated innate immune response in the treatment of neuroblastoma

Holger Lode
Interleukin-2 adds toxicity to long term infusion treatment regimen of ch14.18/CHO antibody without measurable additional activity in relapsed/refractory neuroblastoma patients

Hans Loibner
Galactose-α-1,3-galactose (α-Gal) glycosylation determinant on ch14.18 antibodies produced by CHO- or SP2/0 cell lines – potential clinical impact

Suzanne P MacFarland
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model

Kimikazu Matsumoto
Impact of radiotherapy and curie score on bone relapse in high-risk neuroblastoma

Shakeel Modak
Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma

Shakeel Modak
Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT)

Jan Molenaar
The iTHER (individualized THERapy) program; personalized cancer treatment for relapsed pediatric cancer

Lucas Moreno
The BEACON-Neuroblastoma ITCC/SIOPEN phase 2 trial for children with relapsed and refractory neuroblastoma: a progress report

Daniel A Morgenstern
Viability Of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes
Robyn T Sussman
CAMKV is a candidate immunotherapeutic target in MYCN-amplified neuroblastoma

Yoshiyuki Takahashi
Significantly reduced relapse rate after KIR ligand incompatible allogeneic cord blood transplantation with nonmyeloablative conditioning for primary stage IV neuroblastoma

Domonique Valteau-Couanet
Validation of a test-dose strategy prior intravenous melphalan in children with renal failure undergoing high-dose chemotherapy with autologous stem cell transplantation

Orazio Vittorio
Dextran-Catechin conjugate targets copper metabolism in neuroblastoma

Saurabh Agarwal
Development of a novel transgenic neuroblastoma tumor model using genome editing

Jessica L Bell
IGF2BP1 harbours prognostic significance by gene gain, diverse expression and interplay with MYCN

Annick Mühlethaler-Mottet
Aldehyde dehydrogenases activity plays a key role in NB aggressive behavior

Noriyuki Nishimura
Rab6B mediates the progression of neuroblastoma through the interaction with MTMR5

Camilla Persson
Characterization of patient-derived xenograft neuroblastoma cells

Anna Philpott
Differentiation of Neuroblastoma is controlled by cdk-mediated regulation of the master regulator transcription factor Ascl1.

Diogo Ribeiro
MYCN-regulated nuclear hormone receptors impact differentiation and survival in neuroblastoma patients

Hisanori Takenobu
CDX1 regulates cancer stemness pathway in neuroblastoma

Yasutoshi Tatsumi
BMCC1, a tumor suppressor protein that facilitates DNA-damage response and apoptosis, is associated with favorable prognosis of neuroblastoma

Nobuyuki Yamamoto
DENN domain protein DENND2A regulates the progression of neuroblastoma

Saurabh Agarwal
Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma

Mark A Applebaum
The identification of hypoxia regulated genes that confer a poor prognosis in neuroblastoma patients

Michael B Armstrong
The MAD Family members, MXI1 and MXI0, display distinct subcellular localization patterns in neuroblastoma

Michael B Armstrong
The expression of Mxi1 and Mxi0 lead to differential effects on neuroblastoma pathogenesis and chemosensitivity.

Eveline Barbieri
Targeting MYCN-amplified neuroblastoma through RORα activation.

Christina L. Chang
Identification of a novel protein that suppresses the ability of NDPK-A to promote the invasiveness of neuroblastoma cells

Jorida Coku
Reduced endoplasmic reticulum (ER)-mitochondria tethering as a cause of multidrug resistance in neuroblastoma
Katleen De Preter
An embryonic stem cell activated FOXM1 transcriptional program marks ultra-high-risk primary neuroblastoma patients for FDI-6 small molecule inhibition

Han-Fei Ding
Molecular control of neuroblastoma stem cell metabolism

Christine Gana
New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma

Giuseppe Giannini
The MRN complex controls replication stress and allows proliferation and survival in MYCN amplified neuroblastoma

Dana-Lynn Koomoa
TRPM7 promotes Neuroblastoma progression

Jacqueline M Kraveka
Curcumin mediated apoptosis in human neuroblastoma cells via ROS and inhibition of sphingomyelin synthase and glycosylceramide synthase

Yuanyuan Li
PPP3CB is a novel prognostic indicator of high-risk neuroblastoma contributing to aggressive behaviors

Martina Morini
Clinical significance of a seven-gene hypoxia signature in neuroblastoma

Annick Mühlethaler-Mottet
The CXCR4/CXCR7/CXCL12 axis is involved in a secondary but complex control of neuroblastoma metastatic cell homing

Sela T Po'uja
Stathmin expression regulates miR-382/PTPN14 expression in neuroblastoma cells

Rachele Rosati
Functional Genomics identifies novel therapeutic targets for retinoic acid combinations

Miriam Rosenberg
A multidisciplinary approach to antigen discovery and immune profiling of Opsoclonus-Myoclonus Ataxia Syndrome associated with Neuroblastoma

Hervé Sartelet
Composite Neuroblastoma: Unique tumours with morphologically and genetically defined intratumoral heterogeneity

Yuting Sun
The histone H3 lysine 4 presenter WDR5 is a potential therapeutic target in N-Myc-induced neuroblastoma.

Arata Tomiyama
The signaling complex of tyrosine phosphatase SHP2 and docking protein ShcC regulates oncogenicity of neuroblastoma cells in a tyrosine-phosphorylation dependent manner.

Catarina Trager
The role of p75NTR during neuronal differentiation of neuroblastoma cells

WELCOME FUNCTION – FOOD & WINE INCLUDED
7:00pm - 9:00pm
Outdoor Plaza
PROGRAM

TUESDAY, 21 JUNE, 2016

KEYNOTE 2 - NEAL ROSEN
8:30am - 9:15am
Chair: Kate Matthay

8:30am  Neal Rosen
Not available at time of print  abs# 33

PLENARY SESSION 2
9:15am - 10:20am
Chairs: Mike Hogarty & Murray Norris

9:15am  Suzanne Vanhauwaert
The *BRIP1/FANCJ* DNA helicase is a druggable 17q driver oncogene involved in G-quadruplex induced replicative stress resistance in neuroblastoma  abs# 34

9:31am  Saurabh Agarwal
MLL1 and JMJD3 regulate neuroblastoma cancer stem cells  abs# 35

9:47am  Liselot Mus
Sensing mutant ALK: capicua and ETV5 as executors of aberrant ALK-driven MAPK signaling in neuroblastoma  abs# 36

10:03am  Jan Koster
*TERT* rearrangements are frequent in neuroblastoma and identify aggressive tumours  abs# 37

INRG PRESENTATION
10:20am - 10:30am

10:20am  Samuel L Volchenboum
INRG Data Commons – A User Journey  abs# 38

MORNING TEA
10:30am - 11:00am
Exhibition Area
PARALLEL 5 - EPIGENETICS
11:00am - 12:30pm
Chairs: Carol Thiele & Takehiko Kamijo

11:00am  Frank Westermann
Integrative genome-scale analysis identifies epigenetic mechanisms of
transcriptional deregulation in unfavorable neuroblastomas  abs# 39

11:15am  Isabelle Janoueix-Lerosey
Dissecting neuroblastoma specific regulatory networks through epigenome mapping
and transcriptional profiling of neuroblastoma and neural crest cell lines  abs# 40

11:30am  Eveline Barbieri
The histone chaperone CHAF1A promotes tumorigenesis and opposes
neuroblastoma differentiation via metabolic reprogramming.  abs# 41

11:45am  Bieke Decaestecker
The TBX2 super-enhancer marked transcription factor on 17q is overexpressed in
neuroblastoma and infers poor prognosis  abs# 42

12:00pm  Shana Claeyts
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven
neuroblastoma through interaction with the PRC2 complex.  abs# 43

12:15pm  Tao Liu
Combination therapy with the bromodomain inhibitor JQ1 and the histone
deaetylase inhibitor panobinostat synergistically reduce LIN28B gene and N-Myc
protein expression and suppress neuroblastoma progression  abs# 44

PARALLEL 6 - TRANSLATIONAL AWARDS SESSION
11:00am - 12:30pm
Chairs: John Maris & Matthias Fischer

11:00am  Angela Bellini
High frequency of mutations in chromatin remodeling genes in neuroblastoma  abs# 45

11:15am  Melinda Halasz
Identification of spliceosomal components as novel therapeutic targets for the
treatment of high-risk, MYCN-driven neuroblastoma  abs# 46

11:30am  Evon Poon
The orally bioavailable small molecule CDK9 inhibitors CYC065 and CCT68127 are
potent inhibitors of MYCN transcription  abs# 47

11:45am  Paul J Wood
Long term, continuous exposure to panobinostat induces terminal differentiation and
long term survival in the TH-NMYC neuroblastoma mouse model  abs# 48

12:00pm  Renata Sano
A novel antibody-drug conjugate directed to the ALK receptor demonstrates efficacy
in models of neuroblastoma  abs# 49

12:15pm  Kellie Haworth
Oncolytic herpes Simplex-1 virotherapy augments chimeric antigen receptor T-Cell
(CAR-T) therapy in Neuroblastomas  abs# 50

LUNCH
12:30pm - 1:30pm
Exhibition Area

ANRA ADVISORY BOARD MEETING
12:30pm - 1:30pm
Meeting room 1 & 2

PARALLEL 7 - BASIC AWARDS SESSION
1:30pm - 3:00pm
Chairs: Rogier Versteeg & Darrell Yamashiro

1:30pm  Joanna Kitlinska
Prenatal stress increases NB tumorigenicity in TH-MYCN mice.  

1:45pm  Daniel R Carter
Identifying mechanisms of neuroblastoma tumorigenesis using single cell transcriptomics

2:00pm  Michael Hogarty
ARID1A and ARID1B mutations in the Swi/Snf BAF chromatin remodeling complex drive poor outcome neuroblastoma

2:15pm  Matthias Fischer
Identification of somatic mutations determining the neuroblastoma phenotype

2:30pm  Matthias Fischer
MYCN and HDAC5 transcriptionally repress CD9 to trigger an invasion-metastasis cascade in neuroblastoma

2:45pm  Gonzalo Lopez
MYCN amplified neuroblastomas require TEAD4 to orchestrate transcriptional programs, exposing a therapeutic vulnerability

PARALLEL 8 - CLINICAL IMAGING, RISK FACTORS AND RESPONSE
1:30pm - 3:00pm  
Meeting room 1 & 2
Chairs: Dominque Valteau-Couanet & Wendy London

1:30pm  Steven G. DuBois
Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG)

1:45pm  Shakeel Modak
Discordance in $^{123}$I-MIBG (MIBG) and $^{18}$FDG positron emitting tomography (PET) scans after multimodality therapy for high-risk neuroblastoma: clinical implications

2:00pm  Yen-Lin Liu
Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma

2:15pm  Daniel A Morgenstern
Towards a model for risk stratification of high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN study.

2:30pm  Julie R. Park
Revisions to the International Neuroblastoma Response Criteria: A consensus statement from the NCI-Clinical Trials Planning Meeting

2:45pm  Barbara Hero
Risk factors for outcome after relapse or progression of localized Neuroblastoma

AFTERNOON TEA
3:00pm - 3:30pm  
Exhibition Area
WORKSHOP 3 - EMERGING TECHNOLOGIES FOR EXPLORATION OF TUMOR HETEROGENEITY, CLONAL EVOLUTION AND PROGRESSION IN NEUROBLASTOMA

3:30pm - 5:00pm
Moderator: Gudrun Schleiermacher

Sponsored by

Genetic heterogeneity and clonal evolution have been shown to play a role in progression of neuroblastoma. Recent data from other malignancies suggest that genetic heterogeneity might reflect not only evidence of competing clones, but also cooperating clonal events. This workshop will focus on neuroblastoma genetic heterogeneity, seeking to explore how recent and emerging technologies such as single cell studies and surrogate samples including circulating tumor DNA (ctDNA) and disseminated/circulating tumor cells (DTC/CTC) and can contribute to the understanding of the role of genetic heterogeneity and clonal evolution in tumor progression. While highlighting technical issues, challenges and pitfalls, the important questions of how these findings can be harnessed for clinical management of neuroblastoma patients will be further discussed.

3:30pm  Spyros Darmanis
         Single cell studies of the brain and its malignancies
4:00pm  John Maris
         The biological and clinical relevance of tumoral heterogeneity and clonal evolution in high-risk neuroblastoma
4:15pm  M. Reza Abbasi
         Impact of bone marrow-derived disseminated neuroblastoma cells on the identification of the relapse seeding clone
4:30pm  Angelika Eggert
         Addressing tumor heterogeneity in NB - potential and challenges of liquid biopsies
4:45pm  Panel Discussion
WORKSHOP 4 - NEXT GENERATION RISK STRATIFICATION: NEW APPROACHES TO IDENTIFY HIGHEST RISK PATIENTS (OR ULTRA HIGH RISK PATIENTS)

3:30pm - 5:00pm
Meeting room 1 & 2
Moderator: Meredith Irwin

Risk stratification approaches that rely on robust clinical and biological prognostic factors have been used to predict outcome and tailor therapies for neuroblastoma patients for more than two decades. Current classification systems utilize clinical, histologic, and genetic factors to identify patients with low, intermediate, or high risk neuroblastoma. Recent advances have resulted in improved patient outcomes; however, long-term survival for high-risk patients remains < 50%. Furthermore, current prognostic factors do not predict which high-risk (HR) neuroblastoma patients will fail to achieve remission with current era therapies. There are many efforts aimed at prospectively identifying the subset of HR patients at highest risk of death, or “ultra-high risk (UHR) patients,” for whom novel therapies may be indicated early on in the course of the disease. Currently there is no uniform definition for UHR and to date, no clinical or genetic determinant(s) reliably identify UHR patients. In this workshop we will highlight recent advances in the discovery of germline and somatic genomic alterations that may predict poor outcome or failure to respond to therapy in the setting of high-risk disease. The potential roles for gene expression signatures and detection of minimal residual disease will also be discussed. Following these presentations there will be a panel discussion to consider how to incorporate these novel prognostic factors into upfront clinical trials and how we may use genomic markers and minimum residual disease status together with current prognostic factors to further refine the next generation of risk classification systems.

3:30pm  Introduction, overview and goals
3:35pm  Sharon Diskin
Can germline and somatic mutations (or rare variants) help us identify "ultra-high risk" neuroblastoma and predict patient outcomes?

3:50pm  Kathleen De Preter
Copy number profiles as prognostic marker for high-risk neuroblastoma patients

4:05pm  Matthias Fischer
Molecular risk stratification of neuroblastoma patients - using RNA, DNA, or both?

4:20pm  Sue Burchill
Clinical impact and technical application of reverse transcriptase polymerase chain reaction to detect neuroblastoma RNAs in bone marrow and blood

4:40pm  Panel Discussion
RAPID FIRE POSTER PRESENTATION 2
5:05pm - 5:25pm

Sharon J. Diskin
Common germline variants at MLF1 and CPZ loci associated with neuroblastoma susceptibility
abs# 295

Tao Liu
Suppressing the expression of a single novel long noncoding RNA leads to neuroblastoma regression or eradication
abs# 298

Shinichi Kiyonari
Identification of new synthetic lethal genes in MYCN-amplified neuroblastoma cells
abs# 363

Zhi Xiong Chen
A non-canonical tumor suppression pathway identified in neuroblastoma – A New Paradigm for Personalized Treatment and Prognosis
abs# 349

Ji Won Lee
Comprehensive analysis of neuroblastoma using high depth cancer gene panel sequencing
abs# 297

Michael M Song
Cell lines (CLs) and patient derived xenografts (PDXs) established from post-mortem neuroblastoma samples display heterogeneity in sensitivity to chemotherapeutic agents commonly utilized in the treatment of high-risk neuroblastoma patients
abs# 293

Keri A Streby
Enhancing 131I-mIBG radiation therapy with oncolytic HSV1716 and NAT gene therapy in high-risk neuroblastoma
abs# 294

Giuseppe Barone
The CHK1 inhibitor CCT244747, alone and in combination with gemcitabine, is active against p53 deficient models of neuroblastoma resistant to chemotherapy
abs# 283

Daniel A Morgenstern
Engraftment following busulfan/melphalan (BuMel) high-dose chemotherapy for high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN trial
abs# 326

Godelieve Tytgat
131Iodine-metaiodobenzylguanidine (131I-MIBG) and autologous stem cell transplantation harvesting and hematological reconstitution in high-risk neuroblastoma patients
abs# 335

Ruth Ladenstein
Prognostic Factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN Trial
abs# 324

Matthew D Aldridge
Establishment of a reproducible methodology and results for molecular radiotherapy dosimetric assessment of 177Lu-DOTATATE in neuroblastoma
abs# 312

Hiroyuki Shichino
Phase I trial of perifosine monotherapy in patients with relapsed or refractory neuroblastoma
abs# 331

Gareth Veal
Busulfan and melphalan pharmacokinetics in high-risk neuroblastoma patients treated on the HR-NBL1/SIOPEN trial
abs# 308

Gudrun Schleiermacher
Genomic profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma
abs# 301

Laurel T. Bate-Eya
High efficacy of the BCL-2 inhibitor venetoclax (ABT-199) in neuroblastoma and rational for combination therapy
abs# 284

Min Kang
Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies
abs# 321
For those with specific interest in abstracts from the Basic, Clinical or Translational categories please use the lists located on page 129 as you walk amongst the posters to find them easily. Posters are arranged in the Exhibition Area in consecutive numerical order. Should you wish to view the entire list of poster abstracts in either Basic, Clinical or Translation divisions, please refer to the ‘app’ where you will find the posters sorted by category. Further information on the ‘app’ is available on page 22. Below is a complete listing of all posters in the Tuesday evening poster session.

**Sponsored by**

**Boris Decarolis**  
Impact of the involvement of the separate body regions in the modified Curie and the SIOPEN mIBG-scoring systems in patients with stage 4 neuroblastoma  
**abs# 263**

**Alexander E. Druy**  
Prognostic significance of imbalanced chromosomal alterations in primary and recurrent neuroblastoma  
**abs# 264**

**Shakeel Modak**  
$^{18}$F-Meta Fluorobenzyl Guanidine (MFBG) Positron Emission Tomography (PET) imaging in patients with Neuroblastoma and other Neuroendocrine Malignancies  
**abs# 265**

**Shakeel Modak**  
$^{124}$I-hu3F8 radioimmuno-positron emission tomography (PET) in patients with neuroblastoma and other GD2-positive malignancies: preliminary results on biodistribution, pharmacokinetics and tumor targeting  
**abs# 266**

**Atsuko Nakazawa**  
A High ALK expression is associated with an unfavorable histology in Neuroblastoma.  
**abs# 267**

**Meng Yao Lu**  
Feasibility of applying F$^{18}$-DOPA hybrid MR-PET to follow-up of neuroblastoma patients  
**abs# 268**

**Divya Sahu**  
Co-expression network analysis reveals long non-coding RNA SNHG1 as a novel biomarker in neuroblastoma  
**abs# 269**

**Gudrun Schleiermacher**  
Post surgical 123I-MIBG SPECT/CT in neuroblastoma  
**abs# 270**

**Gudrun Schleiermacher**  
High-risk neuroblastoma without MYCN amplification in patients between 12 and 18 months: Is there a hidden low-risk patient group?  
**abs# 271**

**Katarzyna Szewczyk**  
The detection and quantification of neuroblastoma metastases in bone marrow using plasmids-targets as standards in QRT-PCR  
**abs# 272**

**Clare J. Twist**  
Validation of image-defined risk factor (IDRF) assignment in patients with intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531  
**abs# 273**

**Godelieve Tytgat**  
Epithelial to mesenchymal transition and minimal residual disease monitoring in neuroblastoma  
**abs# 274**

**Sam Volchenboum**  
Computer-assisted Curie scoring for Metaiodobenzylguanidine (mIBG) Scans in Patients with Neuroblastoma  
**abs# 275**

**Kristoffer von Stedingk**  
Lack of adaptive immunity markers is associated with early death amongst high-risk neuroblastomas  
**abs# 276**

**Larry L Wang**  
High-MKI neuroblastomas - MYC-family-driven tumors with augmented expression of MYCN/MYC protein behaves more aggressively than Non-MYC-family-driven tumors: a report from the Children’s Oncology Group  
**abs# 277**

**Daniel Weiser**  
XPO1 is overabundant in patients with neuroblastoma at ultra-high-risk for treatment failure: rationale for refined diagnostic risk stratification and targeted therapy  
**abs# 278**
Akihiro Yoneda
Incidence of stage IV neuroblastoma patients 2-5 years of age was increased after the cessation of mass screening in Japan

Elise Young
Molecular Karyotyping in Neuroblastoma – time to stop G-banding.

Clarke Anderson
Neural stem cell-mediated enzyme/prodrug therapy for neuroblastoma: translation to the clinic

Giuseppe Barone
A comprehensive preclinical study of ALK inhibitors for the efficacious treatment of ALK<sup>F1174L</sup>/MYCN-driven neuroblastoma

Giuseppe Barone
The CHK1 inhibitor CCT244747, alone and in combination with gemcitabine, is active against p53 deficient models of neuroblastoma resistant to chemotherapy.

Laurel T. Bate-Eya
High efficacy of the BCL-2 inhibitor venetoclax (ABT-199) in neuroblastoma and rational for combination therapy.

Jeffrey Bond
Neuroblastoma drug response profiles are associated with gene expression profiles

Mario Capasso
A high-throughput drug screening of FDA approved anti-cancer compounds suggests candidate tyrosine kinase inhibitors for repositioning in neuroblastoma therapy

Emmy Dolman
ITCC Biology: pre-clinical targeted drug development for high-risk pediatric cancers

Andrea Flynn
Effects on tumor cells and the immune microenvironment may both contribute to the anti-tumor activities of DFMO in neuroblastoma pre-clinical models

Jennifer H Foster
Targeting NEDD8: a novel approach to treating neuroblastoma

Laura D. Gamble
Targeting the polyamine pathway in combination with conventional chemotherapy for the treatment of childhood neuroblastoma

Sina Gogolin
Targeting cell cycle and transcriptional CDKs using Roniciclib leads to significant high cell death in MYCN/MYC-activated neuroblastoma cells

Mitsuteru Hiwatari
Identification of novel pathways and molecules able to down regulate oncogenes expression by in vitro drug screening approaches in neuroblastoma cells.

Michael M Song
Cell lines (CLs) and patient derived xenografts (PDXs) established from post-mortem neuroblastoma samples display heterogeneity in sensitivity to chemotherapeutic agents commonly utilized in the treatment of high-risk neuroblastoma patients.

Keri A Streby
Enhancing <sup>131</sup>I-mIBG radiation therapy with oncolytic HSV1716 and NAT gene therapy in high-risk neuroblastoma

Sharon J. Diskin
Common germline variants at MLF1 and CPZ loci associated with neuroblastoma susceptibility

Angelika Eggert
Mutational dynamics between primary and relapse neuroblastoma involve the Hippo/YAP1 pathway and genes relevant for epithelial-mesenchymal transition

Ji Won Lee
Comprehensive analysis of neuroblastoma using high depth cancer gene panel sequencing

Tao Liu
Suppressing the expression of a single novel long noncoding RNA leads to neuroblastoma regression or eradication

Dries Rombaut
Long non-coding RNAs as novel components in the TP53 pathway
Gudrun Schleiermacher
Genomic profiling in low and intermediate risk neuroblastoma to refine treatment stratification and improve patient outcome – LINES: a SIOPEN Trial

Gudrun Schleiermacher
Genomic profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma

Robert W Schnepp
The chromatin associated protein JARID2 Is a novel LIN28B-Influenced target in neuroblastoma

Masatoshi Takagi
Loss of ATM function confers risk for advanced stage neuroblastoma but provides a therapeutic target for poly-ADP ribose polymerase inhibitors

Ya-Hui Tsai
Investigation on the miRNA signature in retinoic acid-resistant neuroblastoma cells as novel therapeutic targets

Christophe Van Neste
Integrated network analysis of G-quadruplex and replicative stress related genes as sources for neuroblastoma genomic instability

Jun Yang
The histone demethylase KDM5A regulates p53 function via a translation mechanism

Alan Van Goethem
Identification of non-invasive biomarkers for treatment response in neuroblastoma by circulating miRNA profiling

Gareth Veal
Busulfan and melphalan pharmacokinetics in high-risk neuroblastoma patients treated on the HR-NBL1/SIOPEN trial

Gareth J Veal
Clinical follow-up of high-risk neuroblastoma patients receiving individualised 13-cis-retinoic acid based on pharmacological exposure as part of a national UK study

Daniel A Morgenstern
Providing information on clinical trials to parents of children with neuroblastoma: a novel liaison in a clinical nurse specialist role.

Clare J. Twist
Premature physeal closure following prolonged fenretinide administration in patients with neuroblastoma

Matthew D Aldridge
Establishment of a reproducible methodology and results for molecular radiotherapy dosimetric assessment of $^{177}$Lu-DOTATATE in neuroblastoma

Julien Fleurence
An anti-O-acetylated GD2 ganglioside antibody for the immunotherapy of High – Grade Diffuse Glioma in children

Mark N Gaze
Immunohistochemical evaluation of target expression in high-risk neuroblastoma samples to facilitate optimisation of molecular radiotherapy

Tomoro Hishiki
Primary tumor resection after high dose chemotherapy with autologous hematopoietic stem cell transplantation is a safe and feasible option. A report from the Japanese neuroblastoma study group (JNBSG)

Tomoko Iehara
Opsoclonus-myoclonus syndrome in neuroblastoma: A report from the Japan Neuroblastoma Study Group (JNBSG)

Minoru MI Ishii
Combination therapy of highly activated natural killer cells and anti-disialoganglioside (GD2) antibody for Neuroblastoma: An experimental study

Merel Jans
Analysis of surgery for Neuroblastoma in The Netherlands

Denis Kachanov
Low-risk neuroblastoma in Russia: therapy results and prognostic factors
Min H Kang
Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies

Shinsuke Kataoka
Long term survival after KIR ligand incompatible allogeneic cord blood transplantation as a salvage therapy for relapsed stage IV neuroblastoma

Anatoly A P Kazantsev
Treatment high-risk neuroblastoma.

Ruth Ladenstein

Daniel A Morgenstern
Primary tumour response to busulfan/melphalan high-dose chemotherapy in patients with high-risk neuroblastoma: a pilot study.

Daniel A Morgenstern
Engraftment following busulfan/melphalan (BuMel) high-dose chemotherapy for high-risk neuroblastoma. A report from the HR-NBL-1/SIOOPEN trial.

Atsushi Narita
Phase I study of anti-GD2 antibody ch14.18/CHO long term infusion in recurrent or refractory neuroblastoma patients in Japan

Sajid Qureshi
Complication of surgery for abdominal neuroblastoma: Chyle Leak

Elizabeth Roundhill
Expression, trafficking and biological significance of mitochondrial MRP1 in neuroblastoma.

Gudrun Schleiermacher
OMS/DES 2011: a Multinational European Trial for Children with Opsoclonus Myoclonus Syndrome

Hiroyuki Shichino
Phase I trial of perifosine monotherapy in patients with relapsed or refractory neuroblastoma

Nikolai Siebert
Generation of a new bicistronic DNA vaccine encoding for tyrosine hydroxylase and IL-15 to induce an active immune response against neuroblastoma

Stefania Sorrentino
Spinal canal invasion in peripheral neuroblastic tumors. Study design and preliminary results of a prospective SIOOPEN Study Registry.

Ryota Souzaki
Creating Three-Dimensional full size model based on preoperative CT images for laparoscopic adrenalectomy and liver biopsy in a case demonstrating adrenal neuroblastoma with liver metastasis

Godelieve Tytgat
131Iodine-metaiodobenzylguanidine (131I-MIBG) and autologous stem cell transplantation harvesting and hematological reconstitution in high-risk neuroblastoma patients.

Keith Wheatley
BEACON-2: design of a SIOOPEN/ITCC multi-arm multi-stage (MAMS) trial for relapsed neuroblastoma

Aleksandra Wieczorek
The role of image defined risk factor (IDRF) in evaluation of the risk of post-surgical kidneys dysfunction in children with neuroblastoma

Darrell J Yamashiro
Targeting activating transcription factor 5 (ATF5) in neuroblastoma with a novel dominant negative inhibitor

Jinhua Zhang
A research of the induction and differentiation therapy for neuroblastoma in children

Maxi Zumpe
Generation of new DNA- and protein vaccines for active immunotherapy against MYCN-expressing neuroblastoma
Carmen Dorneburg  
Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma  
abs# 341

Simon Durand  
Growth advantage and oncogene addiction of neuroblastoma cells bearing an ALK mutation  
abs# 342

Marco Gualandi  
Impact of Neuroblastoma recurrent mutations on embryonic sympatho-adrenal development  
abs# 343

Naonori Kawakubo  
Natural antibody against neuroblastoma of the TH-MYCN transgenic mice has CDC activity  
abs# 344

Venkatadri Kolla  
MYCN Amplicon in Neuroblastoma (NB) Cell Lines  
abs# 345

Zhihui Liu  
Identification of CASZ1 nuclear export signal (NES) reveals potential mechanism for loss of CASZ1 tumor suppressor activity in neuroblastoma (NB)  
abs# 346

Jelena Milosevic  
PPM1D/Wip1, the candidate gene on 17q contributing to neuroblastoma development  
abs# 347

Katharina Batzke  
Modulation of immune responses and radioresistance by neuroblastoma-derived and host-derived TrkB-target Galectin-1  
abs# 348

Zhi Xiong Chen  
A non-canonical tumor suppression pathway identified in neuroblastoma – a new paradigm for personalized treatment and prognosis  
abs# 349

Johanna Dzieran  
MYCN-induced miR-18a interferes with estrogen and NGF signaling to maintain an undifferentiated and more aggressive phenotype in neuroblastoma  
abs# 350

Selene Elifio-Esposito  
NPY/NPY5R copy number increases in relapsing neuroblastoma  
abs# 351

Mona Friedrich  
MYCN-dependent regulation of gene expression during the cell cycle in neuroblastoma cells  
abs# 352

Jixuan Gao  
The ABC transporter ABCE1 is a therapeutic target in neuroblastoma  
abs# 353

Giuseppe Giannini  
The Poly (ADP-ribose) polymerase inhibitor olaparib causes mitotic catastrophe in MYCN amplified neuroblastoma by enhancing replication stress  
abs# 354

Sabine Hartlieb  
Alternative lengthening of telomeres in primary neuroblastoma specimens – a genomic, epigenomic & proteomic approach  
abs# 355

Charlotte Haunch-Smith  
Characterisation of neuroblastoma cells isolated from bone marrow aspirates of children with stage 4 disease at diagnosis: an NCRI CCL CSG Neuroblastoma Group Study.  
abs# 356

Zhongyan Hua  
PI3K and MAPK pathways mediate the BDNF/TrkB-increased migration and invasion in Neuroblastoma cells  
abs# 357

Shinya Ikematsu  
Inhibition of the growth factor midkine in neuroblastoma by an Okinawan agricultural product  
abs# 358

Niloufar Javanmardi  
Neuroblastoma: telomere elongation is responsible for aggressive behavior  
abs# 359

Maria Kavallaris  
Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signalling and enhanced transendothelial migration  
abs# 360

Patrick Kim  
Combination of HDAC and mitochondrial-targeted metabolism inhibitors exhibits strong therapeutic synergy in vitro and in vivo against neuroblastoma  
abs# 361
Satoshi Kishida
The involvement of Midkine, a growth factor exacerbating cisplatin-induced nephrotoxicity, in cisplatin resistance of neuroblastoma cells

Shinichi Kiyonari
Identification of new synthetic lethal genes in MYCN-amplified neuroblastoma cells

Jayne Murray
Suppression of Multidrug resistance protein 4 inhibits neuroblastoma growth both in vitro and in vivo

Ganna Oliynyk
MYCN mediates metabolic plasticity in childhood neuroblastoma

Annalisa Pezzolo
GOLPH3 regulates Golgi shape and is activated by DNA damage in neuroblastoma cell lines

Navin Pinto
Patterns of PD-1, PD-L1 and PD-L2 Expression in Neuroblastoma

María Victoria Ruiz Pérez
Targeting fatty acid synthesis to induce neuroblastoma differentiation

Alica Torkov
Blinding the CYCLOPS – Neuroblastoma vulnerabilities unveiled by genomic loss

Sieu L Tran
Elevated expression of dyskerin is a potential therapeutic target with a telomerase-independent role in Myc/N-Myc-driven neuroblastoma

Veronica Veschi
Epigenetic siRNA and chemosensitivity screens identify a vulnerability to SETD8 inhibition through reactivation of p53 canonical pathway in Neuroblastoma

My D Vu
The expression of AT Rich Interactive Domain 1A (ARID1A) in Neuroblastoma

Amber K Weiner
Integrative approach to define the cell surface landscape in neuroblastoma

Pei-Yi Wu
Calreticulin-dependent VEGF expression promotes neuroblastoma differentiation

Denise Yu
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4

Tina Zheng
Human stem cell models for relapse neuroblastoma

TRANSPORT FROM CAIRNS CONVENTION CENTRE TO TJAPUKAI
7:15pm - 7:45pm

TJAPUKAI CAIRNS DINNER & SHOW OR DINNER ALONE
7:45pm - 9:45pm
Tjapukai Aboriginal Cultural Park

TRANSPORT FROM TJAPUKAI TO CONFERENCE HOTELS
9:45pm - 10:15pm
PROGRAM

WEDNESDAY, 22 JUNE, 2016

KEYNOTE 3 - KIMBERLY STEGMAIER
8:30am - 9:15am
Chair: Andy Pearson

8:30am  Kimberly Stegmaier
Emerging epigenetic targets in MYCN-amplified neuroblastoma

PLENARY SESSION 3
9:15am - 10:20am  Hall A
Chairs: Angelika Eggert & Godfrey Chan

9:15am  Rogier Versteeg
Neuroblastoma is bi-phasic and includes classical neuro-epithelial cells and chemoresistant mesenchymal cells

9:31am  Pauline Depuydt
Distal chromosome 6q-deletion defines a subgroup of ultra-high risk neuroblastoma patients

9:47am  Yael P Mosse
Chemical proteomics defines kinome responses to ALK inhibition in neuroblastoma

10:03am  Shahab Asgharzadeh
Enhancing efficacy of immune checkpoint blockade with anti-macrophage targeted therapy

MORNING TEA
10:20am - 11:00am  Exhibition Area

PARALLEL 9 - MYCN AND TUMOUR BIOLOGY
11:00am - 12:15pm  Hall A
Chairs: Isabelle Janoueix-Lerosey & Kenji Kadomatsu

11:00am  Giovanni Perini
Altering the MYCN/MAX ratio in a drosophila MYCN model leads to homeotic transformation of the eye to wing through deregulation of specific HOX genes

11:15am  Johan van Nes
Identification and reprogramming of mesenchymal-type cells in neuroblastoma

11:30am  Marie Arsenian-Henriksson
Induction of a metabolic switch in neuroblastoma and in other human cancer types upon targeting MYC

11:45am  Andrew E Tee
The histone methyltransferase DOT1L induces neuroblastoma progression by regulating gene transcription

12:00pm  Angela Bellini
Frequency of high and low level clonal ALK mutations in high risk neuroblastoma patients. A SIOPEN study
PARALLEL 10 - HIGH RISK NEUROBLASTOMA
11:00am - 12:15pm
Meeting room 1 & 2
Chairs: Purna Kurkure & Lisa Diller

11:00am  Thorsten Simon
I-131-meta-iodobenzylguanidine therapy improves survival in high-risk neuroblastoma patients with mIBG positive residual metastatic disease  abs# 85

11:15am  Adela Cañete
Did we improve results in infants with MYCN Amplified Neuroblastoma? Comparison of treatment strategy and outcomes in INES 99.4 and HR-NBL1/ SIOPEN. A SIOPEN Study  abs# 86

11:30am  Meaghan Granger
Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma. A Children’s Oncology Group (COG) study  abs# 87

11:45am  Giselle Sholler
DFMO maintains remission and increases overall survival in high risk neuroblastoma: results of a phase II prevention trial  abs# 88

12:00pm  Thorsten Simon
The benefit of myeloablative chemotherapy with autologous stem cell transplantation in high-risk neuroblastoma patients is stable during long term follow-up. Results of the NB97 trial  abs# 89

FREE AFTERNOON
OPTIONAL REEF TRIP TO GREEN ISLAND 12:15 – 17:20
12:15pm - 5:20pm
Lunch boxes can be collected in the ground floor foyer.

DINNER ALONE
PROGRAM

THURSDAY, 23 JUNE, 2016

ANZCHOG WELCOME
9:00am - 9:10am

PLENARY SESSION 4
9:10am - 10:30am
Chairs: Gudrun Schleiermacher & Sue Cohn

9:10am  
Julie R Park
A Phase 3 randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children’s Oncology Group (COG) study

9:26am  
Rajen Mody
Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group (COG)

9:42am  
Mark A Applebaum
Second malignancies in patients with neuroblastoma: a report from the international neuroblastoma risk group project

9:58am  
Ulrike Pötschger
The way towards an international mIBG skeletal score for high risk neuroblastoma: the statistical perspective

10:14am  
Ruth Ladenstein
Final results of the randomised short term infusion (STI) of ch14.18/CHOmAB immunotherapy in combination with Aldesleukin: a report on outcome and toxicities from the HR-NBL1/SIOPEN trial

MORNING TEA
10:30am - 11:00am
Exhibition Area
PARALLEL 11 - BIOMARKERS AND NOVEL APPROACHES
11:00am - 12:30pm  Meeting room 1 & 2
Chairs: Per Kogner & Pat Reynolds

11:00am  **Iedan Verly**
Catecholamine metabolites: novel diagnostic insight, correlations with biological features and prediction of clinical outcome in patients with neuroblastoma  abs# 95

11:15am  **Anne Hakkert**
High frequency of Cytosine to Adenine mutations in neuroblastoma correlates with genomic aberrations in 8-Oxo-Guanine repair pathway  abs# 96

11:30am  **Geertrui Denecker**
The FOXM1 target gene BIRC5 (survivin) is a top ranked dosage sensitive gene located on the common large copy number 17q gained segment in neuroblastoma.  abs# 97

11:45am  **Belamy B Cheung**
Identification of novel small molecule compounds to restore sensitivity to trophic factor withdrawal in MYCN-initiated death resistant cells  abs# 98

12:00pm  **Sabine Taschner-Mandl**
Metronomic Topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells *in vitro* and *in vivo* by therapy induced senescence  abs# 99

12:15pm  **Michael M Song**
High MYCN, low MYC, low CERS4, and low anti-apoptotic BCL2 gene family expression are associated with sensitivity to fenretinide in neuroblastoma cell lines and PDXs  abs# 100

PARALLEL 12 - IMMUNOTHERAPY AND EARLY PHASE TRIALS
11:00am - 12:30pm  Meeting room 3 & 4
Chairs: Daniel Morgenstern & Rajen Mody

11:00am  **Annette Kuenkele**
Preclinical assessment of CD171-directed CAR T cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility  abs# 101

11:15am  **Holger N Lode**
Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) showed clinical efficacy and improved toxicity in patients with high risk neuroblastoma.  abs# 102

11:30am  **Sara M. Federico**
Humanized anti-gd2 antibody (hu14.18k322a) with Chemotherapy +/- parental natural killer (nk) cells in children with recurrent/ refractory Neuroblastoma  abs# 103

11:45am  **Shahab Asgharzadeh**
Tumor-associated macrophage polarization state and the dynamic nature of PDL1 expression in neuroblastomas  abs# 104

12:00pm  **Julie R Park**
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A phase 1 study of autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors (CAR) for recurrent/refractory high-risk neuroblastoma (HR-NB)  abs# 105

12:15pm  **Steven G. DuBois**
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium  abs# 106
NEUROBLASTOMA UPDATE - 1
11:00am - 12:30pm
Chairs: Sue Cohn & Andy Pearson

11:00am  Sharon Diskin
Overview of neuroblastoma epidemiology and genetic predisposition  abs# 107
11:20am  Frank Speleman
Actionable genomic mutations  abs# 108
11:40am  Susan Cohn
Updates on the International Neuroblastoma Risk Group (INRG). Classification System and Interactive INRG Database (iINRGdb)  abs# 109
12:00pm  Gudrun Schleiermacher
Overview of treatment for low- and intermediate-risk patients  abs# 110

LUNCH
12:30pm - 1:30pm
Exhibition Area

FOLLOW-UP ANRA ADVISORY BOARD MEETING
12:30pm - 1:30pm
Meeting room 3 & 4

INDUSTRY SPONSORED WORKSHOP: UNITED THERAPEUTICS
12:45pm - 1:25pm
Meeting room 1 & 2

PARALLEL 13 - GENOME WIDE ANALYSIS AND GENETIC VARIATION
1:30pm - 3:30pm
Chairs: Frank Westermann & Katleen De Preter

1:30pm  Mario Capasso
Whole exome and deep targeted sequencing of clinically aggressive neuroblastomas reveal recurrent somatic mutations in pathways involved in cancer progression  abs# 111
1:45pm  Sharon J. Diskin
Identification of germline mutations in 776 children with neuroblastoma  abs# 112
2:00pm  Fakhera Ikram
Fusion-transcripts are associated with an unfavourable phenotype in neuroblastoma  abs# 113
2:15pm  Paul Deveau
Clonal reconstruction in neuroblastoma shows enrichment of mutations in cell survival and DNA-repair pathways at relapse  abs# 114
2:30pm  Frank Westermann
Chromosomal rearrangements juxtapose active enhancer elements to oncogenes in high-risk neuroblastoma  abs# 115
2:45pm  Carolina Rosswog
Molecular risk assessment of neuroblastoma patients eliminates the necessity of clinical prognostic markers  abs# 116
3:00pm  Mark A Applebaum
Genetic variants in BARD1 and KIF15 are associated with MYCN-amplification in neuroblastoma  abs# 117
3:15pm  Navin Pinto
Pharmacogenetics of treatment response in patients with high-risk neuroblastoma, a Children’s Oncology Group study  abs# 118
PARALLEL 14 - CLINICAL AWARDS SESSION
1:30pm - 3:30pm
Chairs: Holger Lode & Jed Nuchtern

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Abstract Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Lucas Moreno</td>
<td>Predicting “early” relapse/progression/death in children with INRGSS Stage M neuroblastoma using clinical and biologic factors: An INRG database analysis</td>
<td>abs# 119</td>
</tr>
<tr>
<td>1:45pm</td>
<td>Meredith S Irwin</td>
<td>Revised Children’s Oncology Group (COG) risk stratification incorporating the international neuroblastoma risk group staging system</td>
<td>abs# 120</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Ji Won Lee</td>
<td>High-dose $^{131}$I-MIBG treatment incorporated into tandem HDCT/auto-SCT for high-risk neuroblastoma: Results of SMC NB-2009 study</td>
<td>abs# 121</td>
</tr>
<tr>
<td>2:15pm</td>
<td>Kelly Huibregtse</td>
<td>Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with $^{131}$I-metaiodobenzylguanidine</td>
<td>abs# 122</td>
</tr>
<tr>
<td>2:30pm</td>
<td>Pablo Berlanga</td>
<td>Central nervous system relapses in patients with high-risk neuroblastoma: the SIOPEN experience</td>
<td>abs# 123</td>
</tr>
<tr>
<td>2:45pm</td>
<td>Andras Heczey</td>
<td>Autologous T cells expressing a GD2 specific chimeric antigen receptor with CD28 and OX40 costimulatory endodomains for children with neuroblastoma</td>
<td>abs# 124</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Holger N Lode</td>
<td>Killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms correlate with antibody-dependent cell-mediated cytotoxicity levels and survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL-2).</td>
<td>abs# 125</td>
</tr>
<tr>
<td>3:15pm</td>
<td>Araz Marachelian</td>
<td>A Phase I Study of Lenalidomide in Combination with ch14.18 and isotretinoin in Patients with Refractory/Recurrent Neuroblastoma (RR-NB): New Approaches to Neuroblastoma Therapy (NANT) Consortium Trial</td>
<td>abs# 126</td>
</tr>
</tbody>
</table>

NEUROBLASTOMA UPDATE - 2
1:30pm - 3:30pm     Hall A
Chairs: Sue Cohn & Andy Pearson

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Abstract Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Julie Park</td>
<td>Overview of treatment for high-risk patients</td>
<td>abs# 127</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Lucas Moreno</td>
<td>Overview of treatment for relapsed disease</td>
<td>abs# 128</td>
</tr>
<tr>
<td>2:30pm</td>
<td>Lisa Diller</td>
<td>Long-term effect of treatment</td>
<td>abs# 129</td>
</tr>
</tbody>
</table>

AFTERNOON TEA
3:30pm - 4:00pm
Exhibition Area

KEYNOTE 4 – STEPHAN GRUPP
4:00pm - 4:45pm
Chair: Julie Park

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Abstract Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00pm</td>
<td>Stephan Grupp</td>
<td>The CAR T cell revolution in cancer therapy</td>
<td>abs# 130</td>
</tr>
</tbody>
</table>
ANR CLOSING CEREMONY
4:45pm - 5:15pm
Chair: Michelle Haber

CONFERENCE DINNER
7:00pm - 11:30pm
“EFFICACY AND SAFETY OF ch14.18/CHO IN NEUROBLASTOMA”

Monday 20th June 2016
12:45pm – 1:25pm
Meeting Room 1&2

Holger N. Lode, MD
Professor and Chair of Pediatrics
University Medicine Greifswald
Germany

Immunotherapy directed against ganglioside GD2 emerges as an important cornerstone in multimodal treatment regimen of neuroblastoma. GD2 is ranked by the national cancer institute of the United States on position 12 of 79 tumor associated antigens and the clinically most advanced concept to exploit GD2 expression on neuroblastoma for therapeutic purposes is passive immunotherapy with monoclonal antibodies (MAB). Clinical efficacy of human/mouse chimeric MAB ch14.18 specific for GD2 was demonstrated in large multi-center clinical trials conducted by independent cooperative groups either used as monotherapy or in combination with cytokines. In Europe ch14.18 was remanufactured in Chinese hamster ovary cells (ch14.18/CHO) and was investigated in multi-center Phase I, II and III clinical trials in frontline treatment regimen and in patients with relapsed and refractory disease. In order to improve tolerability of the treatment, long term continuous infusion was evaluate suggesting that this is the preferred method of ch14.18 delivery. A summary of results of ch14.18/CHO therapy across clinical trials will be reviewed and discussed underlining efficacy and safety of this MAB for children with NB.

“Establishing a New Standard of Care for High-Risk Neuroblastoma Patients – our practical experience”

Thursday 23rd June 2016
12:45pm – 1:25pm
Meeting Room 1&2

We are delighted to invite you to attend the symposium sponsored by United Therapeutics Europe, Limited at this year’s Advances in Neuroblastoma Research (ANR) 2016 Congress, entitled “Establishing a New Standard of Care for High-Risk Neuroblastoma Patients – our practical experience”. The symposium will raise knowledge of Unituxin® (dinutuximab) as the only approved immunotherapy for the treatment of high-risk neuroblastoma, demonstrating the clinical risks and benefits of this therapeutic advance versus previous standard of care. It is an opportunity to examine the clinical application and role of Unituxin immunotherapy in patients, and to share experience in current best-practice approaches to Unituxin treatment optimisation through a series of case studies.

The meeting will be co-chaired by two leading European experts in the management of high-risk neuroblastoma who also have experience using Unituxin immunotherapy.
- Dr. Jaume Mora (Department of Hematology and Oncology, Hospital Sant Joan de Deu (HSJD) Barcelona, Spain)
- Dr Stergios Zacharoulis (Paediatric Oncology Consultant, Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK)

We look forward to your attendance in what we hope will be an insightful, practical and enjoyable session.

Unituxin is not registered for use in Australia. Unituxin is approved by the European Commission and the US Food and Drug Administration for the treatment of high-risk neuroblastoma in paediatric patients.

A satellite symposium organised by United Therapeutics Europe, Limited (not included in the main event CME/CPD credit offering). ANR 2016 has provided space for this industry session. The programme was independently produced, not subject to review by ANR, and is not part of the scientific/educational programme offered by ANR 2016.
NEUROBLASTOMA PARENTS DAY

FRIDAY 24TH JUNE, 2016

TEA & COFFEE
08:30am - 09:00am

WELCOME AND OVERVIEW OF THE DAY’S AGENDA
09:00am - 09:10am
Chair: Donna Drew

Meeting room 6

HIGH STAKES, DIFFICULT CHOICES: NAVIGATING THE MAZE OF CANCER THERAPY
09:10am - 10:00am
Chair: Donna Drew

Donna Ludwinski, Solving Kids’ Cancer

Making informed and strategic decisions about treatments creates a huge burden of responsibility for parents of children diagnosed with neuroblastoma. Information sources now range from oncologists and web-based medical journals to social media. The key elements of clinical research, and perspectives on past, present and future therapies provide the context for understanding current advances in research. With mutual trust and respect in the doctor-parent relationship, informed parents are best equipped for the difficult task of making choices for their child.

GENETICS
10:00am - 10:40am
Chair: Donna Drew

John Maris, The Children’s Hospital of Philadelphia

PARALLEL - IMMUNOTHERAPY AND NEUROBLASTOMA
11:00am - 11:40am
Chair: Toby Trahair
Holger Lode, University of Medicine Greifswald

PARALLEL - NURSING SYMPOSIUM “BREAKING BAD NEWS”
11:00am - 11:40am
Chair: Donna Drew

Donna Ludwinski, Solving Kids’ Cancer

Delivering bad news, and helping parents (and patients) absorb and cope with the bad news is a major challenge for medical professionals. This requires understanding the parent perspective of diagnosis, disease trajectory, informed consent, and managing family expectations in phase I and phase II trials. Nurses play an integral role in supporting parents transitioning from curative intent to palliative care in hospice and in decisions made in end-of-life care. Nursing delegates will have opportunity to share scenarios they faced with families receiving bad news for open discussion and learn from others’ experience.

MORNING TEA
10:40am - 11:00am
Mezzanine Level Foyer

PARALLEL - NURSING SYMPOSIUM “BREAKING BAD NEWS”
11:00am - 11:40am
Chair: Donna Drew

Donna Ludwinski, Solving Kids’ Cancer

Delivering bad news, and helping parents (and patients) absorb and cope with the bad news is a major challenge for medical professionals. This requires understanding the parent perspective of diagnosis, disease trajectory, informed consent, and managing family expectations in phase I and phase II trials. Nurses play an integral role in supporting parents transitioning from curative intent to palliative care in hospice and in decisions made in end-of-life care. Nursing delegates will have opportunity to share scenarios they faced with families receiving bad news for open discussion and learn from others’ experience.
NEW THERAPIES
11:40am - 12:20pm
Chair: Toby Trahair
Julie Park, Seattle Children’s Hospital

Meeting room 6

LUNCH
12:30pm - 1:30pm
Mezzanine Level Foyer

TARGETED RADIATION
1:30pm - 2:10pm
Chair: Chris Williams
Mark Gaze, University College Hospital London

Meeting room 6

SURVIVORSHIP AND LATE AFFECTS
2:10pm - 2:50pm
Chair: Chris Williams
Richard Cohn, Sydney Children’s Hospital

Meeting room 6

AFTERNOON TEA
3:00pm - 3:20pm
Mezzanine Level Foyer

A FAMILY TELLS THEIR STORY
3:20pm - 4:00pm
Chair: Donna Drew

Meeting room 6

PANEL DISCUSSION
4:00pm - 6:00pm
Chair: Glenn Marshall
Panel: Donna Ludwinski, John Maris, Julie Park, Richard Cohn, Glenn Marshall, Sydney Children’s Hospital, Toby Trahair, Sydney Children’s Hospital

Meeting room 6

ROUND UP AND CLOSE
6:00pm - 6:05pm
Chair: Donna Drew

Meeting room 6

DINNER
6:05pm